Epithelial ovarian cancer (OvCa) is associated with high mortality and, as the majority (475%) of women with OvCa have metastatic disease at the time of diagnosis, rates of survival have not changed appreciably over 30 years. A mechanistic understanding of OvCa initiation and progression is hindered by the complexity of genetic and/or environmental initiating events and lack of clarity regarding the cell(s) or tissue(s) of origin. Metastasis of OvCa involves direct extension or exfoliation of cells and cellular aggregates into the peritoneal cavity, survival of matrix-detached cells in a complex ascites fluid phase and subsequent adhesion to the mesothelium lining covering abdominal organs to establish secondary lesions containing host stromal and inflammatory components. Development of experimental models to recapitulate this unique mechanism of metastasis presents a remarkable scientific challenge, and many approaches used to study other solid tumors (for example, lung, colon and breast) are not transferable to OvCa research given the distinct metastasis pattern and unique tumor microenvironment (TME). This review will discuss recent progress in the development and refinement of experimental models to study OvCa. Novel cellular, three-dimensional organotypic, and ex vivo models are considered and the current in vivo models summarized. The review critically evaluates currently available genetic mouse models of OvCa, the emergence of xenopatients and the utility of the hen model to study OvCa prevention, tumorigenesis, metastasis and chemoresistance. As these new approaches more accurately recapitulate the complex TME, it is predicted that new opportunities for enhanced understanding of disease progression, metastasis and therapeutic response will emerge.
INTRODUCTION
Ovarian cancer (OvCa) continues to be a poorly understood disease with an extremely poor prognosis. Its cell of origin is still unknown and researchers have only begun to elucidate its molecular mechanisms. Several molecular changes have been confirmed in human tumors and functionally characterized in cell and animal models (for example, p53, PI3 kinase, ARID1, K-ras and BRCA1, 2). [1] [2] [3] [4] [5] [6] However, no genetic alteration has, as yet, been found to be a clinically 'actionable' genetic change. One reason for the slow progress made in understanding the biology of OvCa and translating that knowledge into substantial clinical benefits has been a lack of clinically representative model systems that mimic the progression of the human disease. As the majority of women diagnosed with epithelial OvCa (475%) have intraabdominal metastasis at the time of diagnosis, models that replicate the molecular events that underlie dissemination are a crucial tool to gain the knowledge necessary for the development of new treatments.
Several excellent reviews discuss the current knowledge of OvCa biology. [1] [2] [3] 7 This review offers a comprehensive overview of experimental models available for the study of OvCa. By reviewing the current state of model systems, the hope is to stimulate discussions on how these models may be improved, as well as to provide a needed reference. The biology of OvCa poses special challenges to the development of model systems. The disease commonly referred to as 'ovarian cancer' is not a single entity, but consists of several histological subtypes (serous, endometrioid, clear cell and mucinous) with distinct molecular aberrations. 1, 3 The site of origin for high-grade serous OvCa, the major histological subtype, is still unknown and is intensely debated. Possible sites include the abdominal peritoneum and the fallopian tube fimbriae, as well as the ovarian surface epithelium (OSE). 7, 8 Moreover, OvCa is distinct from most other solid tumors in those hematogenous metastasis is rare. 9 The initial early event in epithelial OvCa metastasis is proteinasemediated shedding into the peritoneal cavity. [10] [11] [12] Intraperitoneal (i.p.) metastatic implants are initiated by single cells and spheroids adhering to peritoneal mesothelial cells and anchoring in the submesothelial matrix to establish secondary lesions. [13] [14] [15] Accumulated peritoneal ascites (often4500 ml) contains a unique non-adherent population of individual tumor cells and multicellular aggregates (spheroids) exposed to a set of microenvironmental cues that promote metastatic implantation. 1, 13, 14 As the mortality of OvCa is directly attributed to disseminated peritoneal metastasis, this distinctive microenvironment provides a marked set of therapeutic challenges and necessitates research that makes use of a suite of model systems to recapitulate specific cellular and molecular events in metastasis.
THREE-DIMENSIONAL CULTURE MODELS OF OVCA TO RECAPITULATE THE TUMOR MICROENVIRONMENT
Ovarian tumors are not a solid matrix of epithelial cells, but rather a mixture of epithelial, stromal, immune and endothelial cells.
This complex tumor microenvironment (TME) includes (1) primary tumor with tumor-associated stromal cells (fibroblasts and mesothelial cells) and inflammatory cells (macrophages and leukocytes); (2) non-adherent cells suspended in ascites with inflammatory and mesothelial cells; and (3) metastases to various parts of peritoneal cavity that contact mesothelial cells, adipocytes and fibroblasts at the metastatic site. 9 This heterogeneity of cell types likely impacts tumor histology, growth potential and ability to evade chemotherapy. Optimal treatment for OvCa patients consists of tumor debulking (removing all tumors 41 mm) followed by chemotherapy. As OvCa is often widely disseminated with many microscopic implants that cannot be surgically removed, leading to disease recurrence within the first 2-3 years, there is a critical need for a more detailed understanding of early events in (re)colonization of metastatic implants. These experimental questions require new model systems that have been designed to recapitulate events occurring in the OvCa TME.
While our knowledge of OvCa biology has largely been derived from experiments using cancer cells grown in two dimensions on plastic, studying OvCa initiation, progression and metastasis in a three-dimensional (3D) system has many advantages. In particular, epithelial cells grown in 3D with extracellular and/or cellular components of the TME exhibit a number of features similar to those of cells in the clinical microenvironment. Therefore, 3D models that incorporate extracellular matrices (ECM) and stromal cells provide an opportunity for understanding the cross-talk between OvCa and stromal cells; for detailed analysis of the contribution of stromal elements to cell adhesion, invasion and nutrient access; and to assess the influence of the TME on tumor cell survival, proliferation and differentiation.
OvCa cells and 3D matrices Initial strategies for creating 3D cultures 16, 17 began with mixing OvCa cell lines or primary cells with different forms of ECM.
The ECM used was typically either a purified series of proteins, such as collagen, or an extract derived from a more complex mixture, such as Matrigel (Corning, Tewksbury, MA, USA). The early events that follow submesothelial matrix contact are modeled by culturing cells on top of 3D collagen gels, allowing the evaluation of changes in gene expression that accompany metastatic anchoring (Figures 1Aa-c) . 2, 18 Matrix penetration, survival and proliferation within the mechanically constrained 3D matrix environment can be modeled by seeding single cells within 3D collagen gels (Figures 1Ad,e) . Indeed, successful growth of a metastatic aggregate requires proliferation within a mechanically constrained matrix microenvironment, a process facilitated by the expression of matrix-degrading proteinases such as membrane type 1 matrix metalloproteinase that promotes proliferation within an interstitial collagen mileu. 19, 20 OvCa cells grown in 3D culture on growth factor-reduced Matrigel exhibit a central hypoxic region, leading to the decreased diffusion and perfusion of drugs. 21 The growth factor-reduced Matrigel OvCa model has been used to screen for drugs that are able to penetrate deep into the hypoxic and acidic region of the 3D culture. 22 Spheroids or multicellular aggregates OvCa spheroids that range in size from 30 to 200 mm can be isolated from patient ascites 23 or produced by growing OvCa cells on non-adherent plates, 24 spinner-flasks, 25 or by using the hanging-drop culture method ( Figure 1B) . 26 Multicellular aggregate formation may facilitate metastasis, as spheroids resist anoikis and can adhere to both omentum and exposed ECM. 13, 14 Adhesion of spheroids initiates a transition from a floating cell population to a peritoneally anchored metastatic lesion. Following adhesion to a collagen surface, the cells acquire unique mRNA profiles that more closely resemble in vivo tumor gene expression profiles. 2 (d) Fluorescence micrograph of individual MCA generated using CellTracker Red-labeled DOV13 cells (scale bar 30 mm). (e) Scanning electron micrograph of MCA generated using DOV13 cells. MCAs were placed in primary fixative (2% glutaraldehyde, 2% paraformaldehyde in 0.1 M Cacodylate buffer pH 7.35) followed by fixation with osmium tetroxide, dehydration in ethanol and critical point drying. Platinum-coated samples were examined using a Hitachi S-4700 Field Emission Scanning Electron Microscope (Hitachi High Technologies, Dallas, TX, USA) (scale bar 50 mm). (f ) Transmission electron micrograph of MCA generated using DOV13 cells. Following primary fixation as described in (e), samples were encapsulated in HistoGel, fixed with osmium tetroxide, dehydrated in ethanol and acetone, infiltrated with Epon/Spurr's resin and cut into ultrathin sections. Sections were mounted on nickel grids, stained with uranyl acetate and Sato's Triple Lead stain, and examined using a JEOL 1400 transmission electron microscope (JEOL USA, Peabody, MA, USA) (scale bar 10 mm). Co-culture of mesothelial with OvCa cells The main sites of OvCa metastasis are mesothelial cell-lined peritoneal surfaces, including the peritoneum, omentum and pleural surface. 15 Notably, in 1985 the first 3D peritoneal culture was used to investigate the adhesion of primary human OvCa cells to primary human mesothelial cells grown on a bovine corneal endothelial cell-derived ECM. 27 Other 3D OvCa co-cultures followed, with cancer cell lines or primary cells grown as monolayers on plastic or as tissue-like multicellular aggregates ( Figure 1B ), which were co-cultured with mesothelial cell monolayers. [28] [29] [30] [31] [32] [33] A derivation of this strategy was the utilization of conditioned medium secreted by mesothelial cells to monitor the influence of secreted factors on cancer cell invasion through ECM. 34 Following adhesion of tumor cells to peritoneal mesothelium, rapid mesothelial cell retraction is initiated, resulting in exposure of the interstitial collagen-rich submesothelial matrix to which OvCa cells avidly adhere via integrin-mediated interactions ( Figure 1A) . 33, 35, 36 The resulting integrin engagement and clustering modify gene expression profiles, altering the expression of genes that potentiate matrix penetration, anchoring and proliferation. 2, 18 Complex 3D organotypic models with multiple cell types and ECM A recent model of OvCa metastasis provides an environment that more closely mimics the in vivo human peritoneal microenvironment, as it includes the superficial layer of the peritoneum ('mesothelium') to include both mesothelial cells and the submesothelial ECM interspersed with primary human peritoneal fibroblasts. 15 The 3D organotypic model uses tumor-derived primary human OvCa cells or cancer cell lines cultured with omentum-derived primary human mesothelial cells, primary human fibroblasts and patient-derived ECM ( Figure 1C ). 37 This model recapitulates key events in OvCa metastasis including adhesion, proliferation and invasion, thereby re-establishing morphological and functional features of the corresponding tissue in vivo. 37 By using fluorescently labeled cells and fluorescence-activated cell sorting, changes in gene or protein levels and post-translational modification can be individually investigated in the cancer cells, mesothelial cells or fibroblasts after co-culture. Thus far, the 3D 'mesothelium-mimetic' organotypic culture has contributed to our understanding of the role of c-Met, 38 MMP-2, 39 HOXA9, 40 E-cadherin, 12 b 3 -integrin 41 and a 5 -integrin 12 in early OvCa metastasis. The 3D organotypic culture of peritoneal metastasis is particularly suited for use as a predictive preclinical model for drug testing, as drug sensitivity in ex vivo and in vivo studies can be recapitulated in the 3D model. 38, 39 Furthermore, this model can be expanded to use other cell types (for example, adipocytes 42 and macrophages) and provides a system to test the effects of treatments on both normal peritoneal cells and tumor cells, and may be modified for use in high-throughput screening (HAK and EL, unpublished).
Peritoneal and organ explants 3D systems using ex vivo human or mouse peritoneal or omental explants are used to evaluate OvCa tumor cell interactions with intact peritoneal tissue (MSS, unpublished). 39, 43 Dissected peritoneal explants can be pinned to optically clear silastic resin and incubated with OvCa cells or multicellular aggregates ( Figure 1D ). Use of fluorescently tagged OvCa cells enables optical monitoring of adherent cells as well as visualization by confocal microscopy. Scanning electron microscopy can also be used to visualize the morphology of early heterogeneous cell-cell adhesive interactions. Furthermore, explants can be histologically sectioned and used to quantify depth of tumor cell penetration under various conditions. This model confers the ability to monitor the extent and kinetics of adhesion, observe early events in peritoneal anchoring and test potential anti-adhesive therapeutics. Similarly, tissue explants can also be used to evaluate preneoplastic changes in potential progenitors from the ovary and fallopian tube. For example, 3D alginate scaffolds have been used to support the ex vivo growth of ovarian surface cells, normal mouse oviducts and baboon fimbria. [44] [45] [46] In the current iteration, these models are limited by the lack of vasculature, immune and endothelial cells, and other extracellular components present in vivo as well as by the ability to provide reproducible conditions only for a short period of time (o1 week). Nevertheless, the development and use of advanced 3D and ex vivo OvCa models can bridge the gap among in vitro studies, OvCa mouse models and the in vivo human disease. The choice of a model system for a given experiment should reflect the experimental question to be addressed and the stage of OvCa metastasis under investigation.
CELL LINES AND XENOGRAFTS
Although OvCa cell lines and primary tissues that recapitulate the molecular diversity, cellular heterogeneity and histology seen in patient tumors are available, there is no uniform collection or structured overview of these valuable reagents. Here, we summarize the most frequently used OvCa cell lines, including those used as xenografts (Supplementary Table S1 ). The positive attributes of cell culture include ease of propagation, relatively low cost, ability to control culture conditions, less heterogeneous cell populations and the presence of side population cells, which represent a renewable source of OvCa stem cells. Cell culture is limited, however, by the absence of the TME, artifacts from prolonged culture conditions in unphysiological culture medium on plastic, high passage number and the lack of patient-matched normal cell counterparts. When these cells are used to generate xenografts, positive attributes include recapitulation of tumor heterogeneity with recruitment of host stromal cells and maintenance of both tumor stroma and tumor/non-tumor vasculature interactions. This is balanced by the time and expense of these models and the maintenance of only a small portion of niche cells that do not represent the entire tumor.
Serous OvCa epithelial cell lines and intraperitoneally derived xenografts Most high-grade serous OvCa cell lines (Supplementary Table S1 ) have been derived from ascites of patients ranging from chemotherapy naïve to heavily treated, with various stage malignancies. 47 Cell lines established from patient whole tumor tissue (rather than ascites), that are considered as platinum sensitive, include HEY, 48 derived from the peritoneal deposit of a moderately differentiated papillary cystadenocarcinoma, 49 and the cisplatin-resistant derivations HeyA8 and HeyC2, both generated by passaging HEY in athymic nude mice. 48 OVCAR- 4 50 was developed from a patient refractory to platinum-based chemotherapy, and Caov-3 51 from the solid components of a serous OvCa before treatment with cyclophosphamide, adriamycin and 5-fluorouracil. Given that taxanes are the second cornerstone of OvCa treatment, a paclitaxel-resistant subline (SKOV3TR) was derived from SKOV3 cells through selection in incrementally increasing paclitaxel concentrations. 52, 53 Some cell lines have been treated with chemotherapeutic agents to produce resistant sublines. 54 Drug-resistant sublines of A2780, which are all cisplatin resistant at the corresponding micromolar values, include CP70, C30 and C200. An adriamycinresistant A2780 cell line, A2780ADR (100 nM resistance and crossresistant to melphalan and vinblastine) 55 and paclitaxel-resistant A2780 sublines, PTX10 and PTX22 (5 and 15 ng/ml, respectively), 56 are also available. The IGROV-1 cell line was derived from the ovarian tumor of a patient with stage III human ovarian adenocarcinoma who had not received chemotherapy. By subjecting the chemotherapy-naïve cells to 0.5 and 1.0 mg/ml cisplatin, IGROV-1/Pt 0.5 and IGROV-1/Pt 1 sublines were developed. The chemoresistant 2008 cell line was established from a serous cystadenocarcinoma of the ovary. Monthly treatment of 2008 with 1 mM cisplatin with subsequent selection resulted in the 2008 *C13 subline. 57 Deep sequencing data for IGROV-1 cells are available 58 and the line is also included in the NCI-60 cell line panel. Indeed, six OvCa cell lines (OVCAR-3, OVCAR-4, OVCAR-5, OVCAR8, IGROV-1 and SKOV3) are included in the NCI-60 cell lines and are used by the NCI for in vitro drug screening. Therefore, they can be considered as the most extensively characterized set of OvCa cell lines, with drug sensitivity, microRNA, mRNA and proteomic profiling data available. 59 Most importantly, their genetic identity can be verified through DNA fingerprinting, 60 allowing reliable confirmation of their identity.
A number of the cell lines are suitable for development as murine xenografts (Supplementary Table S1 ; Figures 2A and B) . OVCAR-3 has successfully been passaged in mice and developed as an i.p. xenograft that retains many characteristics of its human tumor counterpart with histology similar to a serous OvCa.
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62 and PEO23 63 were collected on relapse after cisplatin and chlorambucil treatment, and represent well-differentiated serous adenocarcinoma cell lines that form xenograft tumors with a histology that is also very similar to a human serous cancer. Passaging the SKOV3 cells in nude mice allowed the development of several sublines (SKOV3ip.1 64 and SKOV3x 65 ) that grow as a disseminated disease in the abdomens of nude mice. This mouse model is characterized by numerous (100-200) small nodules on the surface of the peritoneum, bowel mesentery and diaphragm and by the transformation of the mouse omentum into a larger tumor, 39, 64, 65 mimicking human advanced stage serous-papillary OvCa (Figure 2A ). When gene expression in SKOV3 was compared with that of SKOV3ip.1, the latter showed upregulation of v-erbb2, FGFR1, MMP-19 and downregulation of nm23B, 66 possibly explaining the rapid growth of these cells as xenografts. OVCAR-3 67 and OVCAR-5 ( Figure 2Ba ) have a similar widely disseminated xenograft growth pattern. In contrast, i.p. injection of HeyA8 cells yields a few large tumors that grow in the ovaries and mouse omentum without peritoneal dissemination (Figure 2Bb) , mimicking a distinct human OvCa growth pattern. 68 Most OvCa cell lines can be successfully transfected or transduced to express fluorescent or bioluminescent vectors to enable longitudinal optical imaging of tumor growth (Figures 2Ab,c and Bc). Furthermore, the i.p. and subcutaneous (s.c.) take rate of human OvCa cell lines can be improved by mixing them before injection with Matrigel. 16 Clear-cell, endometrioid and mucinous OvCa cell lines Clear-cell carcinoma, which is by definition a poorly differentiated high-grade tumor, is represented by several OvCa cell lines (Supplementary Table S1 ), including ES-2, 69 TOV-21G, 70 OVISE and OVTOKO, 71 and TYK-nu and OVMANA. 72 ES-2 cells exhibit low-tomoderate resistance to a number of chemotherapeutic agents, including doxorubicin, cisplatin and etoposide. OVISE and OVTOKO were established from metastatic tumors of two patients after treatment with five to six courses of chemotherapy. Both lines are insensitive to cisplatin, doxorubicin, cyclophosphamide and etoposide. Interestingly, i.p. injection of the OVTOKO cells yields peritoneal implantation and distant metastasis in a mouse model, whereas OVISE cells showed no dissemination and metastasis. OVISE contains a homozygous ARID1A mutation often observed in human clear-cell cancers. 6 Both TYK-nu and OVMANA have been fully sequenced, and a PIK3CA mutation in OVMANA was identified 72 that recapitulates the genetic changes observed in human clear-cell OvCa. 5 Endometrioid OvCa is represented by several cell lines (Supplementary Table S1 ). The first endometrioid cell line was MDAH2774, developed from cells in the ascitic fluid from a patient with endometrioid OvCa and forms tumors in nude mice.
73 59M was established from the ascitic fluid sample of patient who previously presented with a synchronous stage IA carcinoma of the ovary and an in situ carcinoma of the endometrium. 74 COV362 was established from a pleural effusion, and like its subclone COV362.4, shows anchorage-independent growth in agar. 75 TOV-112D was derived from a grade 3, stage FIGO IIIC endometrioid OvCa. 70 A mouse endometrioid cancer cell line 76 has been established from the Lox-STOP-Lox (LSL)-KRas G12D ;Pten fl/fl mouse model. 77 EFO-27, representing a mucinous papillary adenocarcinoma, was derived from a solid omental metastasis. 47 Primary ovarian and fallopian tube cells, immortalized lines and establishing lines from primary ovarian tumors Establishing primary OvCa cells has remained a challenge as the optimal cell culture medium and ECM to successfully and reproducibly culture primary OvCa has remained elusive even though various methods have been published. During the initial process of establishing a cell line from a patient tumor rapidly growing contaminating cells, such as fibroblastic and stromal cells, can outcompete the cancer cells in culture. Precautions to avoid non-cancer cell contamination include Percoll gradient separation and isolation with CD45 antibodies. 78, 79 Other methods to isolate primary OvCa cells from ascites and solid tumor tissue include enriching tumor cells using immunomagnetic beads coupled to EpCAM antibodies 80 or filtration through a nylon cell strainer 81 and the use of optimized media previously shown to enhance the growth of breast cancer cells. 82 The primary cells may be characterized by EpCAM and HE4 protein expression and CK7 mRNA expression. 81 As the OvCa cell of origin may be the abdominal peritoneum, the surface epithelium of the ovary 7 or the fimbriated end of the fallopian tube, 83 culturing the primary epithelial cells from these sites is crucial to identifying the pathways involved in the neoplastic transformation of serous OvCa. However, when attempting to propagate these primary epithelia in vitro, culture conditions induce senescence and differentiation. Propagation of human IOSE (immortalized ovarian surface epithelium) cells 84 and fallopian tube fimbria has been made possible by stable transfection with SV40 T antigen. 85, 86 For example, IOSE-29 does not form tumors, while its neoplastic counterpart IOSE-29EC forms s.c. and i.p. tumors in SCID mice. 87 Immortalized fallopian tube cell lines used for i.p. injection retain gross, histological, immunophenotypical and genomic characteristics similar to human high-grade OvCa. 8, 88 When fimbrial cells are cultured on collagen-coated transwells, cell polarization is enhanced, which allows the investigation of DNA damage from chemotherapy and other sources. 88 The use of a 3D alginate scaffold also supports the growth of normal mouse oviducts and ovarian surface cells, as well as baboon fimbria. [44] [45] [46] A human fallopian tube cell line has also been established from tumor tissue. 89 Mouse and rat OvCa cell lines The syngeneic mouse model allows OvCa initiation directly from mouse OSE (MOSE). MOSE are scraped from the mouse bursa and are passaged in culture on plastic until phenotypic changes occur, such as the loss of cell contact inhibition, which results in cellular mounds and changes in cell morphology. 90 During neoplastic progression in the cell culture dish, the tumor-suppressor proteins E-cadherin and connexin-43 are lost, distinguishing early from late MOSE. 91 When MOSE are injected i.p. into C57BL6 mice, ascites and metastatic tumors form by about 90 days, 92 while s.c. injected cells cause solid tumor formation confined to the injection area. When non-transformed cells are injected i.p. and s.c., no tumor formation is observed. The most commonly used mouse OvCa cell line is ID8, developed in vitro from ovaries of the C57BL6 mouse strain. 90 The MOSE cells IG10 and IF5 are cognate tumor-inducing clonal cell lines which in vivo have very different survival times and tumor loads (IF5: 182±3 days, IG10 72±2 days).
Although the transformation into MOSE occurs in vitro, the MOSE system may to some extent recapitulate progression of normal OSE to an epithelial OvCa. A rat ovarian orthotopic xenograft variant has been reported that uses the spontaneously immortalized rat surface ovarian epithelial cell line NuTu-19 in Fisher 344 immunocompetent rat hosts. In this model, development of pelvic extension and peritoneal metastases were dependent upon the number of injected cells. 93 The syngeneic mouse or rat orthotopic models are very useful for studies requiring the preservation of an intact immune system and can be used to confirm results obtained with xenograft models.
Cell line authentication Good cell culture practices and the observation, monitoring, and documentation of cell morphology, behavior, and growth rates will reduce the frequency of cell misidentification. Changes may indicate microbial contamination, genotypic drift due to high passage number, or cross-contamination with another cell line. Given these daily risks and the tremendous implications of using the wrong cell line for experiments, the authentication of cell lines is now being emphasized by scientific journals and granting agencies. Human cell lines should be regularly authenticated and identified using DNA short-tandem repeat profiling. 94 Although OvCa cell lines derived from a multitude of subtypes are available, and multiple OvCa cell lines have been assessed in a single study, availability of a collection of regularly authenticated, mycoplasma tested, and well characterized epithelial OvCa cell lines would be optimal, a need in the field highlighted by a recent report on the extent of OvCa cell line misidentification. 95 Ideally, the cell lines would be accompanied by extensive genetic/epigenetic and other molecular information.
OvCa stem cells OvCa stem cells have now been isolated from a number of sources, including primary tumors, ascites, and established OvCa cell lines. 53, [96] [97] [98] [99] The first report of the isolation and identification of stem cells from OvCa patients described two ascites-derived clones able to form multicellular-aggregate, anchorage-independent spheres in culture, and serially propagate xenograft tumors in nude mice that were histopathologically similar to their parental tumors. 96 A number of surface markers have been used to isolate stem cells from primary patient OvCa (Supplementary Table S2 ). In addition, subpopulations of tumorigenic stem-like 'side populations' cells in cultures of OVCAR3, IGROV-1 and SK-OV-3 have been reported. 98, 100 Since these represent a small population of chemoresistant cells in a tumor, the development of model systems that include stem cells may lead to a better understanding of tumorigenesis and drug resistance in OvCa.
Orthotopic implantation of cell lines and whole tissue tumor grafts ('xenopatients') Early events in metastasis cannot be fully appreciated when i.p. xenografts are used, since they rely on the artificial dispersion of single cell suspensions of cancer cells in the peritoneal cavity, rather than dissociation of metastatic cells from an intact primary tumor tissue. Orthotopic ovarian xenografts may mimic more closely the process of dissemination from the primary ovarian tumor relative to the i.p. xenografts discussed above and are therefore well suited for studying metastasis. However, there are significant anatomic differences between rodents, which have a closed bursa at the end of a long and coiled fallopian tube with longitudinal folds enclosing the ovary, 101 and humans where the tube is straight, short, and the epithelium is exposed to the peritoneal cavity. Several approaches have been utilized for orthotopic mouse models: injection of cancer cell lines under the ovarian bursa, implantation of human or murine tumor fragments adjacent to the ovary or under the renal capsule, and i.p. injection of minced human tumor. [102] [103] [104] [105] Critical steps in the metastatic process are invasion through the ovarian bursa followed by peritoneal spread with colonization and invasion of the organs in the peritoneal cavity. Intrabursal injection of OvCa cells causes tumor formation in the ovary, but peritoneal dissemination may not occur. Moreover, only a small volume (45 ml) can be injected under the fat pad without causing mechanical disruption of the bursa and peritoneal spillage.
Implantation of whole human OvCa tissue fragments under or adjacent to the ovarian bursa of SCID mice generates ovarian tumors that histologically resemble the tumor of origin. 102 In this model, tumor take rate is B65% at 16 weeks and production of malignant ascites has been recorded, although metastases occurred infrequently. However, in one study using initial implantation of intact human ovarian tumor fragments, metastatic dissemination initiated from orthotopic ovarian tumors was reported following serial passage of human xenografts in the ovarian fat pad. 106 After several passages, peritoneal spread was recorded, resembling the clinical features of the human disease. Higher tumor take (B95%) is observed when fragments of human ovarian tumors are implanted under the renal capsule of SCID mice, 104 perhaps reflecting a more permissive host milieu facilitated by the rich kidney vasculature. While tumor growth was generally slow and observed metastases were rare, the histological and immunophenotypic characteristics of the original tumor are preserved in the tumor graft. Growth of less aggressive tumors, such as benign, borderline, and granulosa tumors is also possible when fragments are implanted under the renal capsule.
An alternative method to implantation of full tissue fragments, which requires mouse surgery, is to inject a finely minced primary human tumor slurry directly i.p. into mice. 107 Mice are then monitored for engraftment using manual palpation and small animal ultrasound. This methodology has led to a high engraftment rate (B74%) from over 200 consecutive patients with untreated ovarian, primary peritoneal and fallopian tube cancers. 105 The 'xenopatients' recapitulated the histological (Figure 2C ), molecular and platinum-sensitivity characteristics of the source patient tumors. Thus, 'xenopatients' could be useful models for assessing response to therapeutic interventions or biomarker discovery in a manner reflecting the behavior of the original tumor. Indeed, response to platinum chemotherapy was recorded in an orthotopic serous fallopian tube explant, mirroring the clinical response of the donor patient. 108 These data suggest that these models, albeit very labor intensive, may be useful tools for individualizing patient therapy.
GENETICALLY ENGINEERED MOUSE MODELS OF OVCA
Genetically engineered mouse models (GEMMs) of OvCa, which can closely recapitulate human disease, have the potential to greatly improve our understanding of OvCa biology. 109 These models, involving genes expressed or deleted specifically in the ovary or the fallopian tube, allow us to evaluate the physiological relevance of defined genetic changes in OvCa and to better understand the mechanistic significance of genetic lesions revealed in human tumors. Such preclinical models are clearly also suited for testing new compounds for cancer prevention 76 and therapy, 110,111 as they can be used to model drug resistance as well as contribute to the discovery and validation of novel serum biomarkers. GEMMs of OvCa are summarized in Supplementary Table S3. GEMM using various combinations of p53, RB, Myc, Akt and Pten Generating GEMMs of OvCa in which the fallopian tube or OSE is specifically targeted has proven difficult due to the lack of defined transcriptional promoters active specifically in these cell types. One of the first animal models of OvCa used the TVA receptor system driven by the epithelial-specific cytokeratin 5 promoter to delete the p53 tumor suppressor in isolated ovarian surface epithelia in vitro. 112 OSE cells in which p53 had been deleted in this manner were then infected in vitro with retroviruses expressing combinations of relevant oncogenes (c-myc, K-ras and/or Akt). The cells, now with altered gene expression, were transplanted into host mice. This process ensured that tumors were unlikely to arise from tissues other than OSE that express cytokeratin 5. These mice developed OvCa with papillary structures consistent with serous OvCa and using these mice it was shown that rapamycin inhibits the growth of tumors depending on Akt activity. 110 Subsequent work showed that a single oncogene, in this case c-Myc, was sufficient to drive OSE tumorigenesis when both p53 and BRCA1 were deleted using the TVA system. 113 Clearly, this model showed that the ovarian surface is capable of forming tumors when the correct oncogene and tumor suppressor gene mutations are introduced.
The lack of defined cell type-specific promoters continues to hinder more conventional transgenic approaches to drive the deletion or activation of relevant tumor suppressors and oncogenes in the OSE. As the promoters used to express genes in OSE are also active in other tissues of Mü llerian origin (fallopian tube, uterus, cervix and ovarian granulosa cells), the origin of emerging 'ovarian' tumors in the mouse model is open to question. One of the most effective promoters used to drive Cre recombinase or other transgenes has been the promoter of the Mü llerian inhibiting substance II receptor (MISRII) gene, also known as the Anti-Mü llerian Hormone Type II Receptor. The MISRII promoter primarily drives transgene expression in the ovarian surface and ovarian granulosa cells, but it also expressed the transgene in the mesenchyme of the oviduct. The first transgenic mouse model to utilize the MISRII promoter used it to drive expression of the SV40 large T antigen (SV40-Tag), a viral oncogene that binds to and inactivates both p53 and all members of the retinoblastoma (Rb) pocket protein family of cell-cycle regulators. As a result, B50% of the animals developed large undifferentiated ovarian adenocarcinomas by 90-100 days. 114 To more effectively control the timing of oncogene expression, an LSL cassette was inserted between the SV40-Tag and the ubiquitous CAG promoter. Oncogene expression was then induced following the direct intrabursal injection of adenovirus expressing Cre recombinase, which, theoretically, only reached oviductal and ovarian surface epithelial cells. 115 Approximately 89% of the pCAG-LSL-SV40-Tag mice injected in this way developed poorly differentiated tumors with metastasis throughout the abdominal cavity, similar to the tumor type and incidence observed when SV40-Tag expression was driven by the MISRII promoter. 114, 115 Thus, both intrabursal injection and MISRII effectively target the ovarian surface, while SV40-Tag expression in the oviductal mesenchyme does not induce oviductal tumors.
Cre-Lox technology has been used more extensively to induce targeted deletion of the Pten tumor suppressor and to activate the K-Ras oncogene. In two separate models, LSL-KRas
G12D
;Pten fl/fl mice were induced to develop ovarian tumors either through adenoviral delivery of Cre 77 or through expression of a Cre transgene under the control of the aforementioned MISRII promoter. 116 The MISRIICre; LSL-KRas
;Pten fl/fl mice develop a form of low-grade epithelial serous cancer derived from the ovarian surface with 100% penetrance. This is currently the only transgenic mouse that models a low-grade serous OvCa. 116 In contrast, when tumors were induced in LSL-KRas
;Pten fl/fl mice by infection of the OSE with adenovirus expressing Cre recombinase, the mice developed endometrioid or poorly differentiated carcinomas ( Figure 2D ). 77 In this model, adenoviral vectors that express Cre recombinase were used to selectively express or delete genes in the ovary. These vectors are injected into the ovarian bursa, theoretically only reaching oviductal, ovarian surface epithelial and bursa cells. However, in practice they sometimes leak out through the injection site and reach uterine tissue. The difference between these two models, both of which target K-Ras and Pten, is the manner in which Cre is delivered. 77, 116 This illustrates the importance of defining the target tissue and developmental timing for deletion/activation of the critical oncogenes and tumor suppressors. For example, follicular depletion and a loss of circulating ovarian hormones such as estrogen are evident in the MISRII-Cre; LSL-KRas
;Pten fl/fl mice, 116 but not in the Ad-Cre; LSL-KRas
;Pten fl/fl mice. 117 To what extent such developmental and follicular effects of transgene expression have a role in tumorigenesis in these mice is not clear.
The Pten tumor suppressor has also been deleted in mice in combination with the Apc tumor suppressor, a signaling molecule in the Wnt/b-catenin pathway. 118 The combined deletion of Pten and Apc by intrabursal injection of Cre recombinase expressing adenovirus resulted in the formation of the endometrioid subtype OvCa in all injected animals, 118 similar to that seen in the Ad-Cre; LSL-KRas G12D ;Pten fl/fl mice. 77 These animals develop a more aggressive phenotype when additional mutations in p53 and PI3Kca are introduced. 119 On the basis of the observation that the AKT pathway is upregulated in human OvCa due to the mutation or amplification of the PIK3CA gene, 5 a mouse model has also been designed with an activating mutation in PI3K (PIK3CA H1047R ) that, when combined with deletion of Pten, led to robust activation of the Akt pathway. After intrabursal adenoviral Cre recombinase injections, the Ad-Cre; PIK3CA H1047R ;Pten fl/fl mice formed ovarian serous adenocarcinomas or granulosa cell tumors. 111 This model has been used to test the efficacy of a PI3K/mTOR pathway inhibitor that was initially effective in inhibiting tumor growth, although the tumors eventually became resistant. 111 These distinct mouse models of OvCa in which Pten is deleted demonstrate that Pten deletion alone is not sufficient for tumor formation, but the specific context of Pten deletion in the OSE or in the OSE and granulosa cells impacts the histotype and grade of the cancer formed.
GEMM of BRCA mutations The BRCA1 and 2 genes are either mutated or silenced by methylation in B20% of all high-grade OvCa. 4 Several conditional BRCA1 and BRCA2 mouse models have been generated. In these, the BRCA allele, flanked by LoxP sites, is deleted either by Cre recombinase expression driven by the MISRII or FSHR promoter, or by adenoviral injection. 117, [120] [121] [122] Targeted deletion of only BRCA1 or BRCA2 in the ovaries is generally not sufficient to induce malignancy, although FSHR promoter-driven deletion of only BRCA1 did generate cystic tumors in one model. 117 The prolonged estrous phase and enhanced estrogen signaling in this model may account for this phenotype, as FSHR is expressed in granulosa, ovarian surface and oviductal cells. 117 Tumor formation may be influenced either by loss of BRCA1 in cells other than those of the ovarian surface or oviduct or by the effects of increased estrogen signaling in cells without BRCA1. Conditional loss of BRCA1 alone (Cre recombinase injection into the bursa) was insufficient to generate tumors and resulted in hyperplasia of the OSE. Combining loss of BRCA1 with loss of p53 resulted in either leiomyosarcomas or no tumors at all, unless the Rb family was also inactivated. 120 Loss of BRCA1 in combination with p53 (BRCA1 LoxP/LoxP p53
LoxP/LoxP ) led to development of a leiomyosarcoma but not a serous OvCa. [120] [121] [122] In a recently reported mouse model, 122 the key event initiating OvCa was the inactivation of the Rb tumor suppressor and related p107/p130 pocket proteins through targeted expression of a mutant form of the SV40-Tag that cannot inactivate p53. This, when combined with the inactivation of p53 and BRCA1 deletion, caused progression to advanced serous OvCa. Similarly, combined loss of p53 and Rb function led to tumor formation. 123 GEMM of fallopian tube cancer As the emergence of the hypothesis that the fallopian tubes may be the primary site of origin of high-grade serous carcinoma, 124 a few models have been introduced to help explain potential genetic causes of tubal cancers. 109 When the oviductal glycoprotein gene promoter was used to drive SV40-Tag expression, mice developed oviductal, uterine and vaginal tumors. 125 Tumor cells were occasionally found in the ovaries, but it was not determined if these represented the primary lesion or a metastasis. Recently, MISRII-Cre; Pten fl/fl ;Dicer fl/fl mice have been generated in which both the Pten and the Dicer gene, required for efficient micro-RNA processing, were deleted in all tissues of Mü llerian duct origin. These mice developed tumors resembling high-grade serous OvCa in the mesenchyme of the oviduct that metastasized to the peritoneum and diaphragm and formed ascites. 126 Histologic analysis and gene expression profiling suggested that these tumors resembled high-grade serous cancer in humans; however, the tumors did not have mutations in BRCA, p53 or deficiencies in homologous repair. 126 This GEMM consistently develops high-grade serous cancer, which metastasizes within the abdominal cavity in a very similar manner to human OvCa. Interestingly, a recent abstract suggests that a Pten fl/fl ;Dicer fl/fl /p53LSL R172H/ þ triple knock-out develops both tubal and ovarian tumors. 127 Thus, it remains to be determined whether the epithelial expression of the 'p53 signature' in BRCA-mutant human OvCa and the formation of serous cancers from the stroma Epithelial ovarian cancer experimental models E Lengyel et al in this mouse model 126 can be reconciled in terms of human disease origin. Lastly, very recent reports suggest that an inducible Pax8-Tet ON system can generate a high-grade serous cancer from the fallopian tube epithelium when p53 and BRCA1 or BRCA2 are simultaneously deleted. 128 The tumors were more likely to be found in the proximal rather than the distal portion of the oviduct. It is the distal portion that is anatomically comparable to the fimbriae of the human fallopian tube and is the more likely site of OvCa formation. This discrepancy in tumor localization when compared with human disease may be explained by the relative strength of the Pax8 promoter in transgenic mice.
GEMMs offer the potential to introduce specific modifications to pathways in a time-and tissue-dependent manner that can help to confirm or deny the importance of genetic mutations in disease onset and chemoresistance. Other advantages of GEMMs are that OvCa develops disease in a shorter time period than non-human primates and chickens allowing studies to be completed quickly. With the use of viral delivery to introduce Cre recombinase, mutations can be turned on and off in different stages of tissue development. Criticism of GEMMs was raised due to concerns that the existing GEMMs do not employ genetic lesions relevant to human high-grade serous cancers and, in many instances, may be driven by inappropriate regulatory sequences and promoters, which may explain, in part, their failure to recapitulate the peritoneal dissemination clinically observed in human OvCa. Unfortunately, OSE do not express a tissue-specific promoter and a promoter only expressed in specific epithelial cells of the fallopian tube (for example, secretory cells 8 ) has not yet been uncovered. Another drawback of GEMMs is that they can produce different phenotypes due to the background strain of the mouse model. 120, 123 As human OvCa is genetically complex, it is likely that genetic mouse models represent only one particular molecular subtype of OvCa, rather than the entire spectrum of the corresponding human disease. 4 THE LAYING HEN MODEL OF EPITHELIAL OVCA One of the major obstacles to progress in OvCa prevention and treatment is a dearth of spontaneous disease models. The primary animal model available for the study of spontaneous epithelial OvCa is the laying hen. 129 As early as the 1960s, reports identified domestic egg-laying hens as probable surrogates for human OvCa, and suggested that they are investigated as potential models. [130] [131] A landmark large-scale epidemiological study documented an age-dependent onset of the disease, with the first occurrence of OvCa observed in hens of 2-2.5 years of age with an incidence of 4%, while in hens aged from 4 to 6 years the incidence was 30-50%. 132 These findings have been confirmed in a recent study demonstrating that the first observable incidence of spontaneous OvCa was in hens aged between 2 and 2.5 years with an incidence of epithelial OvCa of all stages that reached a peak of nearly 60% at 4 years. 133 A distinct advantage of preclinical studies in laying hens is that large-scale studies with hundreds of animals, conducted over extended periods of time, can be performed at relatively little cost. After a hen has completed her second year of laying, producing from 300 to 500 eggs, she has ovulated approximately the same number of times as a woman who has undergone menopause, when the risk of OvCa increases dramatically. 134 A considerable body of epidemiological data supports the link between the number of lifetime ovulations and OvCa risk. Specifically, studies using the domestic hen support the 'incessant ovulation' hypothesis by showing that when ovulation is arrested in hens, either (i) pharmacologically by dosing with progestins, 135 (ii) using a model of restricted ovulation through nutrient deprivation or (iii) via genetic selection for low-egg laying variants, the incidence of OvCa is lower. [135] [136] [137] The high rate of OvCa in egg-laying hens could be the consequence of genomic damage to the OSE associated with incessant ovulations or may indirectly result from facilitated genetic changes or impaired DNA repair, which ultimately lead to the development of OvCa in the hen. A direct relationship between ovulation and OvCa remains to be determined. 129 Description of the hen model Epithelial OvCa in the hen presents with many features of the human disease ( Figures 3A and B) including heterogeneity with at least four clearly distinguishable histological subtypes. In contrast to human OvCa, in which serous disease represents 70% of latestage disease, 50% of late-stage tumors in the hen have histologic features of endometrioid carcinoma in the primary tumor and corresponding peritoneal metastases. 138, 139 However, similarly to their human counterparts, hens exhibit clear-cell, endometrioid, mucinous and serous histological subtypes ( Figure 3C ). The clinical presentation in hens is similar to that in women, in that hens develop substantial volumes of ascites fluid, peritoneal dissemination of metastases and pulmonary emboli. Hens develop solid tumors in the lung parenchyma, which is rare in women with advanced serous OvCa, but may be observed in human endometrioid or clear-cell cancers. 140 Certain molecular markers of human OvCa are reproduced in the hen, including early expression of E-cadherin ( Figure 3D ), 139 upregulation of COX-1, 141 alterations in p53, K-Ras and Her2/ neu, 142 expression of CA125 143 and several surrogate immunohistochemical markers, including PCNA, p27, TGFb1, cytokeratin AE1/AE3, pan cytokeratin, EGFR, Lewis Y, CEA, Tag 72 and erbB-2. 144 Gene profiling studies and bioinformatics comparisons between laying hen and human cancer gene expression patterns have further demonstrated the conservation of genetic lesions associated with OvCa and histotype-specific mutations. 142, 145, 146 Because of the importance of the chicken as a meat animal and its extensive use as a model for developmental studies, robust genomic resources for the chicken have been developed, including cDNA, long-oligo and GeneChip genome arrays (Affymetrix, Santa Clara, CA, USA). 147, 148 The chicken epigenome has also been mapped. 149 Extensive chicken genomic resources are available via the NCBI, 150 the Genome Institute at Washington University, and in a recently published collection of chicken genomic resources. 151 
Prevention
The first preclinical intervention study in the laying hen evaluated the efficacy of medroxyprogesterone acetate (Depo-Provera, Pfizer Inc., New York, NY, USA) in reducing the frequency of spontaneously developing reproductive tract adenocarcinoma, showing a 15% risk reduction in animals treated with the progestin. 135 The authors observed that the high rate of reproductive tract adenocarcinoma further supported the use of the laying hen model of spontaneous ovarian carcinogenesis to test chemoprevention strategies. A recent chemoprevention trial in hens studied treatment with progestin alone, estrogen alone and progestin plus estrogen. 152 Results show that treatment with progestin alone and in combination with estrogen decreased the prevalence of OvCa with a concomitant reduction in egg laying. 135, 152 Both groups concluded that their findings were consistent with the theory that a reduction in ovulatory events may prevent the development of ovarian adenocarcinoma. 135, 152 The utility of the hen model for preclinical evaluation of therapeutic modalities for the prevention of OvCa (reviewed by Rodriguez 153 ) has been demonstrated in studies testing the efficacy of progestins, 135, 152 non-steroidal antiinflammatories 154 and dietary intervention with flaxseed. 155 Studies of early OvCa in hens A distinct advantage of the hen model of OvCa is that the disease arises spontaneously in chickens; and therefore, presents Epithelial ovarian cancer experimental models E Lengyel et al investigators with the opportunity to study the initial events leading to OvCa, to identify targets for prevention, and to devise and test interventions. One example of an early event in OvCa development that has been observed in hens and corroborated in human clinical specimens is the presence of anti-ovarian auto antibodies in the serum of hens with early-stage OvCa. 156, 157 Another example is the increased expression of E-cadherin in hen OvCa, which is clearly seen at the point of neoplastic transformation where normal surface epithelium transitions morphologically into precursor lesions that develop into early primary tumor sites (as shown in Figures 3Da,c) . 139 Similar patterns of increased E-cadherin in inclusion cysts of human ovarian tumors have been described. 7 In addition, the pattern of expression of tubal genes in primary ovarian tumors of the hen 158 and repetition of the 'p53-signature' in preneoplastic lesions of the tubal and OSE of the hen 141 are conserved in the hen analogous to humans.
Imaging in hens Doppler ultrasonography has been employed to analyze the kinetics of an ultrasound contrast agent used to identify and follow ovarian tumor-associated neo-angiogenesis in early-stage OvCa in the hen. Findings were corroborated on necropsy. 155, 159 The kinetics of the ultrasound contrast agent was shown to be indicative of ovarian tumor-associated neo-angiogenesis in earlystage OvCa. The use of contrast-enhanced ultrasound for the detection of early ovarian tumors demonstrates the potential for the development of new clinical diagnostics tools using the hen model. Moreover, the hen model may also be useful for testing the efficacy of different contrast agents in a preclinical setting.
Limitations and challenges
There has been very slow progress in the development of stable cell lines derived from chicken OvCa or ascites for mechanistic studies in hens. Ovarian surface epithelial cells, tumor cells from primary cancer and tumor cells isolated from ascites fluid from hens have been described, but as yet these studies have been limited to primary cultures or cell cultures with low passage numbers. 160 Similarly, there has been very little progress in the development of transgenic chicken models for the manipulation of targeted genes by overexpression, mutation, ablation and silencing. Promising studies, however, have shown that chick embryos can be genetically manipulated, offering hope for the eventual development of transgenic chicken models of OvCa. 161, 162 Another challenge of working with hens is the limited availability of chicken-specific reagents, such as antibodies for immunohistochemical analyses. A panel of commercially available surrogate cancer antigen antibodies has been examined for their cross-reactivity in hens 144 and successfully adapted for the use with hen tumor tissue using robust antigen-retrieval procedures. However, despite the clearly demonstrated power of the hen model and its potential for evaluating therapeutics and preventatives, only a handful of investigators have taken advantage of the model. Access to experimental poultry facilities and lack of capacity for chickens in standard biomedical vivarium facilities limit more widespread adoption of the hen as the standard animal model for OvCa research.
SUMMARY
Within the past 5 years, significant advancement has been made in developing a more comprehensive suite of tools with which to experimentally address the pathobiologic mechanisms that underlie the poor survival of OvCa patients. Despite this progress, the conduct of experimental translational research in OvCa remains limited by substantial challenges. For example, a large number of OvCa cell lines have been derived and maintained in culture, some of which exhibit a chemoresistant phenotype. The value of this resource would be substantially enhanced by the establishment of a 'biobase' collection of regularly authenticated, well-characterized and well-annotated cell lines for distribution to the research community, similar to the resource available to the breast cancer research community. 163 Access to patient-matched normal and tumor cells, normal epithelial and mesenchymal cells from other primary sources (for example, fallopian tube), and enhanced access to well-annotated patient tissue would also facilitate research progress. Several complex 3D and organotypic models of OvCa metastasis have been developed that take into account the cell and tissue architecture and the contributions of ECM as well as stromal and inflammatory cells in the TME. Lacking, however, are models that contribute to our understanding of the very earliest events in OvCa metastasis; the shedding of cells from the primary tumor. Use of these models to elucidate molecular events that initiate and regulate the 'terminal transition' from freefloating ascitic cell or multicellular aggregate to peritoneally anchored metastatic lesion may identify novel therapeutic targets to block metastasis. A challenge will be adaptation of these 3D and organotypic models to a high-throughput format to facilitate drug screening. The use of murine OvCa models with orthotopic injection into the peritoneal cavity, ovarian bursa or kidney capsule has proven utility to address a number of important research questions. However, evolution in our understanding of OvCa initiation, progression and early stages of metastasis is hampered by the need for improved genetic models.
Identification of more precise tissue-specific promoters to target genetic lesions (or sets of mutations) identified in human OvCa tumors to specific tissues in the reproductive tract (ovarian epithelium, fimbriae of fallopian tube, etc.) would promote progress. In this regard, the laying hen model of spontaneous OvCa holds promise and the development of additional research tools, reagents and approaches for use in this model system is warranted. Finally, as we realize that 'ovarian cancer' is many diseases, subtype-specific models will need to be developed and tested. With careful calibration of reagents and experimental models, together with enhanced collaboration, we are poised for significant advancement of our goal to identify novel, effective and personalized approaches to detect and treat OvCa. ABBREVIATIONS ECM, extracellular matrix; GEMM, genetically engineered mouse model; IOSE, immortalized ovarian surface epithelium; i.p., intraperitoneal; LSL, Lox-STOP-Lox; MISRII, Mü llerian inhibiting substance II receptor; MOSE, mouse ovarian surface epithelium; OvCa, ovarian cancer; RB, retinoblastoma; s.c., subcutaneous; TME, tumor microenvironment
